SWTX Stock Overview
SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer.
SpringWorks Therapeutics Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$37.19|
|52 Week High||US$89.75|
|52 Week Low||US$33.33|
|1 Month Change||-21.07%|
|3 Month Change||-33.11%|
|1 Year Change||-52.46%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||64.34%|
Recent News & Updates
SpringWorks Therapeutics: Rating Buy Ahead Of Mid-Year Data Releases
Data from Phase 3 trial for Nirogacestat in treating desmoid tumors and Phase 2 combination trial with anti-BCMA antibody Blenrep in relapsed/refractory multiple myeloma is expected in mid-year. The company has multiple partnerships (including with Pfizer, GlaxoSmithKline, Janssen, Seattle Biosciences, Allogene, etc.) to combine Nirogacestat with their anti-BCMA therapies. The stock could have a 50% return potential after the data from the above trials.
Companies Like SpringWorks Therapeutics (NASDAQ:SWTX) Can Afford To Invest In Growth
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
SpringWorks Is A Biotech To Watch With Several Partnerships And Solid Drug Pipeline
Results from the phase 3 DeFi study using Nirogacestat as a monotherapy for patients with desmoid tumors are expected to be released end of 2021 or early 2022. Nirogacestat is being explored in 7 combinations trials for the treatment of patients with multiple myeloma. The global multiple myeloma market is expected to reach $19.8 billion by 2027. Most recent partnership for SpringWorks' Nirogacestat was with AbbVie, and it becomes 7th one targeting patients with multiple myeloma.
|SWTX||US Biotechs||US Market|
Return vs Industry: SWTX underperformed the US Biotechs industry which returned -21.7% over the past year.
Return vs Market: SWTX underperformed the US Market which returned -12.9% over the past year.
|SWTX Average Weekly Movement||13.1%|
|Biotechs Industry Average Movement||12.4%|
|Market Average Movement||7.9%|
|10% most volatile stocks in US Market||16.9%|
|10% least volatile stocks in US Market||3.0%|
Stable Share Price: SWTX is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 13% a week.
Volatility Over Time: SWTX's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors. The company is also developing mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas, as well as Phase 1/2a clinical trial for the treatment of NF1-PN; mirdametinib + lifirafenib, a combination therapy that is in Phase 1b/2 clinical trial in patients with advanced or refractory solid tumors; and mirdametinib in monotherapy and combination approaches to treat solid tumors.
SpringWorks Therapeutics Fundamentals Summary
|SWTX fundamental statistics|
Is SWTX overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|SWTX income statement (TTM)|
|Cost of Revenue||US$0|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||-4.21|
|Net Profit Margin||0.00%|
How did SWTX perform over the long term?See historical performance and comparison
Is SpringWorks Therapeutics undervalued compared to its fair value and its price relative to the market?
Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PB vs Industry
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate SWTX's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate SWTX's fair value for valuation analysis.
Price To Earnings Ratio
PE vs Industry: SWTX is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: SWTX is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate SWTX's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: SWTX is overvalued based on its PB Ratio (4.8x) compared to the US Biotechs industry average (1.5x).
How is SpringWorks Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?
Future Growth Score2/6
Future Growth Score 2/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: SWTX is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: SWTX is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: SWTX is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: SWTX's revenue (64.3% per year) is forecast to grow faster than the US market (7.8% per year).
High Growth Revenue: SWTX's revenue (64.3% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: SWTX is forecast to be unprofitable in 3 years.
How has SpringWorks Therapeutics performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: SWTX is currently unprofitable.
Growing Profit Margin: SWTX is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: SWTX is unprofitable, and losses have increased over the past 5 years at a rate of 54.9% per year.
Accelerating Growth: Unable to compare SWTX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: SWTX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (96.9%).
Return on Equity
High ROE: SWTX has a negative Return on Equity (-54.65%), as it is currently unprofitable.
How is SpringWorks Therapeutics's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: SWTX's short term assets ($356.0M) exceed its short term liabilities ($23.2M).
Long Term Liabilities: SWTX's short term assets ($356.0M) exceed its long term liabilities ($5.5M).
Debt to Equity History and Analysis
Debt Level: SWTX is debt free.
Reducing Debt: SWTX has not had any debt for past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: SWTX has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: SWTX has sufficient cash runway for 1.8 years if free cash flow continues to reduce at historical rates of 49.3% each year.
What is SpringWorks Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate SWTX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate SWTX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if SWTX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if SWTX's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as SWTX has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Saqib Islam (51 yo)
Mr. Saqib Islam, J.D. serves as Chief Executive Officer and Director at SpringWorks Therapeutics, Inc. since August 2018. He serves as an Independent Director of Passage Bio, Inc. since March 2019. Mr. Isl...
CEO Compensation Analysis
Compensation vs Market: Saqib's total compensation ($USD17.54M) is above average for companies of similar size in the US market ($USD5.44M).
Compensation vs Earnings: Saqib's compensation has increased whilst the company is unprofitable.
Experienced Management: SWTX's management team is not considered experienced ( 2 years average tenure), which suggests a new team.
Experienced Board: SWTX's board of directors are considered experienced (4.8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
SpringWorks Therapeutics, Inc.'s employee growth, exchange listings and data sources
- Name: SpringWorks Therapeutics, Inc.
- Ticker: SWTX
- Exchange: NasdaqGS
- Founded: 2017
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$1.821b
- Shares outstanding: 48.95m
- Website: https://www.springworkstx.com
Number of Employees
- SpringWorks Therapeutics, Inc.
- 100 Washington Boulevard
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/05/21 00:00|
|End of Day Share Price||2022/05/20 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.